Press Release: Novartis Tafinlar(R) (dabrafenib) -2-

Novartis is on Twitter. Sign up to follow @Novartis at https://twitter.com/novartisnews https://twitter.com/novartisnews

For Novartis multimedia content, please visit https://www.novartis.com/news/media-library https://www.novartis.com/news/media-library

For questions about the site or required registration, please contact media.relations@novartis.com

References

1. Bouffet, E MD. Primary analysis of a phase II trial of dabrafenib plus

trametinib (dab + tram) in BRAF V600--mutant pediatric low-grade glioma

(pLGG). 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.

Abstract #LBA2002.

2. Lassaletta A, et al. J Clin Oncol. 2017;35:2934-2941

3. Mistry M, et al. J Clin Oncol. 2015;33:1015-1022

4. Hargrave, D MD. Dabrafenib + trametinib (dab + tram) in

relapsed/refractory (r/r) BRAF V600--mutant pediatric high-grade glioma

(pHGG): Primary analysis of a phase II trial. 2022 American Society of

Clinical Oncology (ASCO) Annual Meeting. Abstract #2009.

5. Ostrom QT, et al. Neuro Oncol. 2021;23(12 suppl 2):iii1-iii105

6. Oberheim Bush NA, Chang S. Treatment Strategies for Low-Grade Glioma in

Adults. J Oncol Pract. 2016 Dec;12(12):1235-1241. doi:

10.1200/JOP.2016.018622. PMID: 27943684.

7. ESMO/Anticancer Fund. Glioma Guide for Patients

8. Louis DN, et al. Acta Neuropathol. 2016;131:803-82

9. Ballester LY, Fuller GN, Powell SZ, Sulman EP, Patel KP, Luthra R, et al.

Retrospective analysis of molecular and immunohistochemical

characterization of 381 primary brain tumors. J Neuropathol Exp Neurol.

2017 Mar 1;76(3):179-88

10. Schindler G, Capper D, Meyer J, Janzarik W, Omran H, Herold-Mende C, et

al. Analysis of BRAF V600E mutation in 1,320 nervous system tumors

reveals high mutation frequencies in pleomorphic xanthoastrocytoma,

ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta

Neuropathol. 2011 Mar;121(3):397-405

11. Turski ML, et al. Mol Cancer Ther. 2016;15:533-547

12. Pratilas C, et al. Curr Top Microbiol Immunol. 2012;355:82-98

13. Tafinlar [prescribing information]. East Hanover, NJ: Novartis

Pharmaceuticals Corp; 2022.

14. Mekinist [prescribing information]. East Hanover, NJ: Novartis

Pharmaceuticals Corp; 2022.

15. Data on file.

# # #

Novartis Media Relations

E-mail: media.relations@novartis.com

Anja von Treskow Dan Connelly

Novartis External Communications Novartis Oncology Communications

+41 79 392 8697 (mobile) +1 862 210 0217 (mobile)

anja.von_treskow@novartis.com daniel.connelly@novartis.com

Julie Masow

Novartis US External Communications

+1 862 579 8456

julie.masow@novartis.com

Novartis Investor Relations

Central investor relations line: +41 61 324 7944

E-mail: investor.relations@novartis.com

Central North America

Samir Shah +41 61 324 7944 Sloan Simpson +1 862 345 4440

Nicole Zinsli-Somm +4 16 132 43809 Alina Levchuk +1 862 778 3372

Isabella Zinck +41 61 324 7188 Parag Mahanti +1 973-876-4912

(END) Dow Jones Newswires

June 06, 2022 08:00 ET (12:00 GMT)